Literature DB >> 16510359

Examination of concurrent exposure to repeated stress and chlorpyrifos on cholinergic, glutamatergic, and monoamine neurotransmitter systems in rat forebrain regions.

Thitiya Pung1, Bradley Klein, Dennis Blodgett, Bernard Jortner, Marion Ehrich.   

Abstract

Repeated stress has been reported to cause reversible impairment in the central nervous system (CNS). It was proposed that alterations in glutamatergic, cholinergic, and monoamine neurotransmitter systems after exposure to stress are initial CNS events contributing to this impairment and that exacerbation could occur with concurrent exposure to cholinesterase inhibitors. Effects of concurrent exposure to repeated stress and chlorpyrifos on activities of acetylcholinesterase (AChE), carboxylesterase, and choline acetyltransferase (ChAT); concentrations of excitatory amino acids, monoamines, and their metabolites; and maximum binding densities (B(max)) and equilibrium dissociation rate constants (K(d)) of glutamatergic N-methyl-d-aspartate (NMDA) and total muscarinic cholinergic receptors were studied in the blood, hippocampus, cerebral cortex, or hypothalamus of adult Long-Evans rats. Stress treatments extended over 28 days included (1) control rats handled 5 days/week; (2) rats restrained 1 h/day for 5 days/week; (3) rats swum 30 min for 1 day/week; or (4) rats restrained 4 days/week and swum for 1 day/week. On day 24, each stress treatment group was randomly divided and injected either with corn oil or chlorpyrifos, 160 mg/kg subcutaneously (sc) (60% of the maximum tolerated dose), 4 h after restraint. Blood and brain tisssues were collected on day 28. Rats restrained and swum had a statistical trend toward increasing concentrations of glutamate in the hippocampus when compared to rats only swum (p = .064). Chlorpyrifos administration decreased restraint-induced elevated aspartate in the hippocampus, and decreased B(max) of total muscarinic receptors in the cerebral cortex. In addition, chlorpyrifos decreased B(max) and K(d) of total muscarinic receptors in the cerebral cortex of swum rats. Results demonstrated that chlorpyrifos inhibited AChE activity in blood, cerebral cortex, and hippocampus, but stress did not affect AChE activity. Carboxylesterase activity was inhibited by chlorpyrifos and by repeated restraint with swim. Swim stress decreased concentrations of norepinephrine in the hippocampus and hypothalamus, and increased concentrations of dopamine and its metabolite, DOPAC, in the hypothalamus. Both stress and chlorpyrifos altered serotonin concentrations, and the interactions of repeated stress and chlorpyrifos on serotonin approached significance in the hippocampus (p = .06) and hypothalamus (p = .08). Therefore, stress models were demonstrated to alter glutamatergic and monoamine responses, whereas chlorpyrifos alone had effects on cholinergic and monoamine systems in the rat CNS. However, the interactions between stress and chlorpyrifos significant at p < 0.05 were restricted to attenuation of elevated aspartate in the hippocampus of restrained with swim rats and decreased K(d) of acetylcholine receptors in the cerebral cortex of swum rats and restrained rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510359     DOI: 10.1080/10915810500527119

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  8 in total

1.  Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events.

Authors:  Neeraj Singh; Vivek Lawana; Jie Luo; Phang Phong; Ahmed Abdalla; Bharathi Palanisamy; Dharmin Rokad; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Anumantha G Kanthasamy; Arthi Kanthasamy
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

2.  Nicotine self-administration differentially modulates glutamate and GABA transmission in hypothalamic paraventricular nucleus to enhance the hypothalamic-pituitary-adrenal response to stress.

Authors:  Guoliang Yu; Hao Chen; Xingjun Wu; Shannon G Matta; Burt M Sharp
Journal:  J Neurochem       Date:  2010-02-25       Impact factor: 5.372

3.  Prenatal nicotine alters the developmental neurotoxicity of postnatal chlorpyrifos directed toward cholinergic systems: better, worse, or just "different?".

Authors:  Theodore A Slotkin; Frederic J Seidler
Journal:  Brain Res Bull       Date:  2014-12-12       Impact factor: 4.077

4.  Impulsivity as long-term sequelae after chlorpyrifos intoxication: time course and individual differences.

Authors:  D Cardona; G López-Crespo; M C Sánchez-Amate; P Flores; F Sánchez-Santed
Journal:  Neurotox Res       Date:  2010-01-20       Impact factor: 3.911

5.  Chlorpyrifos developmental neurotoxicity: interaction with glucocorticoids in PC12 cells.

Authors:  Theodore A Slotkin; Jennifer Card; Frederic J Seidler
Journal:  Neurotoxicol Teratol       Date:  2012-07-14       Impact factor: 3.763

6.  The effect of consequent exposure of stress and dermal application of low doses of chlorpyrifos on the expression of glial fibrillary acidic protein in the hippocampus of adult mice.

Authors:  Kian Loong Lim; Annie Tay; Vishna Devi Nadarajah; Nilesh Kumar Mitra
Journal:  J Occup Med Toxicol       Date:  2011-03-08       Impact factor: 2.646

7.  Mechanism for the acute effects of organophosphate pesticides on the adult 5-HT system.

Authors:  Sarah J Judge; Claire Y Savy; Matthew Campbell; Rebecca Dodds; Larissa Kruger Gomes; Grace Laws; Anna Watson; Peter G Blain; Christopher M Morris; Sarah E Gartside
Journal:  Chem Biol Interact       Date:  2015-12-22       Impact factor: 5.192

8.  Exposure to organophosphates reduces the expression of neurotrophic factors in neonatal rat brain regions: similarities and differences in the effects of chlorpyrifos and diazinon on the fibroblast growth factor superfamily.

Authors:  Theodore A Slotkin; Frederic J Seidler; Fabio Fumagalli
Journal:  Environ Health Perspect       Date:  2007-02-27       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.